Sangamo Therapeutics (NASDAQ:SGMO) Earns “Buy” Rating from HC Wainwright

Sangamo Therapeutics (NASDAQ:SGMO)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $10.00 price objective on the biopharmaceutical company’s stock.

A number of other brokerages have also recently issued reports on SGMO. Wall Street Zen raised shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. Barclays cut their target price on shares of Sangamo Therapeutics from $9.00 to $5.00 and set an “overweight” rating for the company in a research report on Wednesday, May 14th. Four investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, Sangamo Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $4.50.

Sangamo Therapeutics Stock Up 3.2%

SGMO stock opened at $0.55 on Thursday. The firm has a market cap of $165.10 million, a PE ratio of -1.89 and a beta of 1.20. The business has a 50 day moving average of $0.53 and a 200-day moving average of $0.64. Sangamo Therapeutics has a 12-month low of $0.41 and a 12-month high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The business had revenue of $18.31 million during the quarter, compared to the consensus estimate of $31.68 million. Sangamo Therapeutics had a negative net margin of 77.48% and a negative return on equity of 293.05%. On average, research analysts expect that Sangamo Therapeutics will post -0.46 earnings per share for the current year.

Hedge Funds Weigh In On Sangamo Therapeutics

Institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. lifted its stake in shares of Sangamo Therapeutics by 679.5% in the 4th quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 21,793 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Sangamo Therapeutics during the 4th quarter valued at approximately $353,000. Two Sigma Investments LP raised its holdings in shares of Sangamo Therapeutics by 222.1% during the 4th quarter. Two Sigma Investments LP now owns 1,012,640 shares of the biopharmaceutical company’s stock worth $1,033,000 after acquiring an additional 698,296 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Sangamo Therapeutics by 179.3% during the 4th quarter. Bank of America Corp DE now owns 331,256 shares of the biopharmaceutical company’s stock worth $338,000 after acquiring an additional 212,638 shares in the last quarter. Finally, GSA Capital Partners LLP increased its position in shares of Sangamo Therapeutics by 2,962.2% during the 1st quarter. GSA Capital Partners LLP now owns 966,202 shares of the biopharmaceutical company’s stock valued at $634,000 after purchasing an additional 934,649 shares during the last quarter. Institutional investors own 56.93% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.